To Evaluate the Effect of MCS® in Prostate Cancer Prevention
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect of MCS® compared with placebo in reducing the risk of
biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of
treatment.